Summer Xia, Hasten Biopharma CEO
April 21, 2023 06:57 AM EDT
Financing
China

Chi­nese biotech start­up adds $315M to the bank af­ter bring­ing 5 Take­da drugs to its fold

Amber Tong

More than two years af­ter ar­riv­ing on the Chi­na bio­phar­ma scene with a $322 mil­lion deal for five of Take­da’s drugs, Has­ten Bio­phar­ma has land­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

J&J takes 340B fight with fed­er­al gov­ern­ment to court

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times